Legacy effects of lifestyle intervention on circulating metabolites in people with impaired glucose tolerance: a cross-sectional analysis of the Da Qing Diabetes Prevention Study

Meng Yu; Xin Qian; Hongmei Jia; Jinping Wang; Siyao He; Xinxing Feng; Yali An; Qiuhong Gong; Hongzhao You; Guangwei Li; Yanyan Chen; Zhongmei Zou

doi:10.1016/j.jpha.2025.101433

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2025 > Accepted Manu

Meng Yu, Xin Qian, Hongmei Jia, Jinping Wang, Siyao He, Xinxing Feng, Yali An, Qiuhong Gong, Hongzhao You, Guangwei Li, Yanyan Chen, Zhongmei Zou. Legacy effects of lifestyle intervention on circulating metabolites in people with impaired glucose tolerance: a cross-sectional analysis of the Da Qing Diabetes Prevention Study[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101433

Citation:

Meng Yu, Xin Qian, Hongmei Jia, Jinping Wang, Siyao He, Xinxing Feng, Yali An, Qiuhong Gong, Hongzhao You, Guangwei Li, Yanyan Chen, Zhongmei Zou. Legacy effects of lifestyle intervention on circulating metabolites in people with impaired glucose tolerance: a cross-sectional analysis of the Da Qing Diabetes Prevention Study[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101433

Citation:

Meng Yu, Xin Qian, Hongmei Jia, Jinping Wang, Siyao He, Xinxing Feng, Yali An, Qiuhong Gong, Hongzhao You, Guangwei Li, Yanyan Chen, Zhongmei Zou. Legacy effects of lifestyle intervention on circulating metabolites in people with impaired glucose tolerance: a cross-sectional analysis of the Da Qing Diabetes Prevention Study[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2025.101433

PDF( 1500 KB)

Legacy effects of lifestyle intervention on circulating metabolites in people with impaired glucose tolerance: a cross-sectional analysis of the Da Qing Diabetes Prevention Study

doi: 10.1016/j.jpha.2025.101433

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China;
2. Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;
3. Department of Cardiology, Da Qing First Hospital, DaQing 163001, China;
4. National Centre for Cardiovascular Diseases, National Clinical Research Centre for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;
5. Department of Endocrinology, China–Japan Friendship Hospital, Beijing 100029, China

Funds:

This study was funded by the Chinese Academy of Medical Sciences, Novo Nordisk Union Diabetes Research Talent Fund. This work was part of the China Da Qing Diabetes Study Follow-Up Study, which was supported by a Centers for Disease Control and Prevention/World Health Organization Cooperative Agreement (U58/CCU424123-01-02), the China-Japan Friendship Hospital, Da Qing First Hospital, Fuwai Hospital, the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2020-I2M-2-006), National Key Clinical Discipline Construction Project 2022 and National Key Clinical Discipline Construction Project 2023.

Received Date: Feb. 21, 2025
Accepted Date: Aug. 09, 2025
Rev Recd Date: Jul. 30, 2025
Available Online: Aug. 14, 2025

Abstract

Abstract

Lifestyle intervention is considered a global consensus for preventing and delaying the development of type 2 diabetes (T2D). This study aims to investigate the differences in metabolites associated with the long-term effect of lifestyle intervention in people with impaired glucose tolerance (IGT). The study enrolled 60 and 57 people with IGT who were originally assigned to the intervention and control (non-intervention) groups in a lifestyle intervention 6-year trial (1986-1992), respectively, as part of the Da Qing Diabetes Prevention Study. In 2006, 14 years after completion of the intervention trial, blood samples were collected for metabolomics analyses and T2D outcomes were assessed. Metabolomics outcomes were not analyzed at baseline. The untargeted metabolomics revealed that 14 plasma metabolites were significantly different between lifestyle intervention and control groups. Targeted metabolomics revealed that plasma concentrations of LysoPC(18:0/0:0) and SM(d18:1/16:1(9Z)) were significantly higher in the lifestyle intervention group compared with the control (16.72 ± 4.75 vs. 1.34 ± 0.40 and 2.60 ± 1.24 vs. 0.40 ± 0.08, P < 0.0001). A 1 μg/mL increase in LysoPC (18:0/0:0) and SM(d18:1/16:1(9Z)) was significantly associated with decreased risk of T2D (odds ratios were 0.82 (95% CI 0.75–0.90) and 0.17 (95% CI 0.07–0.39)) in all participants after adjusting for clinical confounders. In this cross-sectional study, the plasma LysoPC(18:0/0:0) and SM(d18:1/16:1(9Z)) differ between IGT people assigned to intervention and control groups 14 years after the 6-year intervention trial, suggesting they may have been related to the long-term legacy effects of these interventions.
- Type 2 diabetes (T2D),
- lifestyle intervention,
- metabolomics,
- protective factors,
- LysoPC(18:0/0:0),
- SM(d18:1/16:1(9Z))

FullText(HTML)

References(27)

References

[1]	H. Sun, P. Saeedi, S. Karuranga, et al., IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045, Diabetes Res Clin Pract 183 (2022) 109119.
[2]	L. Wang, W. Peng, Z. Zhao, et al., Prevalence and Treatment of Diabetes in China, 2013-2018, Jama 326 (2021) 2498-2506.
[3]	L. Ji, Current challenges of diabetes and metabolic disorders in China, Diabetes Obes Metab 25 Suppl 1 (2023) 3-4.
[4]	Y. Chen, P. Zhang, J. Wang, et al., Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study, Diabetologia 64 (2021) 1279-1287.
[5]	G. Li, P. Zhang, J. Wang, et al., The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study, Lancet 371 (2008) 1783-1789.
[6]	E.D. Parker, J. Lin, T. Mahoney, et al., Economic Costs of Diabetes in the U.S. in 2022, Diabetes Care 47 (2024) 26-43.
[7]	J.M. Lemp, C. Bommer, M. Xie, et al., Quasi-experimental evaluation of a nationwide diabetes prevention programme, Nature 624 (2023) 138-144.
[8]	J. Lindstrom, M. Peltonen, J.G. Eriksson, et al., Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS), Diabetologia 56 (2013) 284-293.
[9]	J. Lindstrom, A. Louheranta, M. Mannelin, et al., The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity, Diabetes Care 26 (2003) 3230-3236.
[10]	The Diabetes Prevention Program (DPP): description of lifestyle intervention, Diabetes Care 25 (2002) 2165-2171.
[11]	W.C. Knowler, E. Barrett-Connor, S.E. Fowler, et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med 346 (2002) 393-403.
[12]	G. Li, P. Zhang, J. Wang, et al., Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study, Lancet Diabetes Endocrinol 2 (2014) 474-480.
[13]	Q. Gong, P. Zhang, J. Wang, et al., Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study, Lancet Diabetes Endocrinol 7 (2019) 452-461.
[14]	X. Qian, J.P. Wang, Q.H. Gong, et al., Non-diabetes status after diagnosis of impaired glucose tolerance and risk of long-term death and vascular complications: A post hoc analysis of the Da Qing Diabetes Prevention Outcome Study, PLoS Med. 21 (2024) 15, e1004419.
[15]	Y. Chen, H. Jia, X. Qian, et al., Circulating Palmitoyl Sphingomyelin Is Associated With Cardiovascular Disease in Individuals With Type 2 Diabetes: Findings From the China Da Qing Diabetes Study, Diabetes Care 45 (2022) 666-673.
[16]	P. Liu, W. Zhu, C. Chen, et al., The mechanisms of lysophosphatidylcholine in the development of diseases, Life Sci 247 (2020) 117443.
[17]	A. Drzazga, H. Kristinsson, M. Salaga, et al., Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner, Mol Cell Endocrinol 472 (2018) 117-125.
[18]	M. Barranco-Altirriba, N. Alonso, R.J.M. Weber, et al., Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus, Cardiovasc. Diabetol. 23 (2024) 13, 109.
[19]	K. Yea, J. Kim, J.H. Yoon, et al., Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes, J Biol Chem 284 (2009) 33833-33840.
[20]	W. Zhang, L. Gong, S. Yang, et al., Lipidomics Profile Changes of Type 2 Diabetes Mellitus with Acute Myocardial Infarction, Disease Markers 2019 (2019) 7614715.
[21]	P.J. Meikle, S.A. Summers, Sphingolipids and phospholipids in insulin resistance and related metabolic disorders, Nat Rev Endocrinol 13 (2017) 79-91.
[22]	J. Iqbal, M.T. Walsh, S.M. Hammad, et al., Sphingolipids and Lipoproteins in Health and Metabolic Disorders, Trends Endocrinol Metab 28 (2017) 506-518.
[23]	W.S. Chew, F. Torta, S. Ji, et al., Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence, JCI Insight 5 (2019).
[24]	C. Razquin, E. Toledo, C.B. Clish, et al., Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial, Diabetes Care 41 (2018) 2617-2624.
[25]	A. Floegel, N. Stefan, Z. Yu, et al., Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach, Diabetes 62 (2013) 639-648.
[26]	A.M. Fretts, F. Imamura, M. Marklund, et al., Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies, Am. J. Clin. Nutr. 109 (2019) 1216-1223.
[27]	S.Y. Wang, C.Y. Hu, H. Lin, et al., Association of circulating long-chain free fatty acids and incident diabetes risk among normoglycemic Chinese adults: a prospective nested case-control study, Am. J. Clin. Nutr. 120 (2024) 336-346.